Regulators clear a colorectal blood test as a Manchester patient receives a new therapy

The United States Food and Drug Administration approved a new blood test for colorectal cancer screening in older adults, including those above age 45. The approval adds a blood test to the tools described for that screening. The report does not say the test replaces colonoscopy. It states the regulatory clearance and the age group named.

Colorectal cancer is a cancer of the colon or rectum. Screening is meant to find disease earlier, and a blood test is a different method from a visual exam of the bowel. This report does not give the test's accuracy rate. It does not name the manufacturer in the short approval note.

Separately, a cancer patient at the Christie hospital in Manchester, in the United Kingdom, became the first to receive the ZI-MA4-1 therapy. The report identifies the hospital, the therapy name, and the fact that this patient was first. It does not describe the cancer type beyond identifying the person as a cancer patient.

The American approval and the Manchester treatment are different medical steps in different countries. One is a screening test cleared for older adults. The other is a first use of a named therapy in a hospital. They are not reported as parts of one clinical trial.

No price is given for the blood test. No survival figure is given for ZI-MA4-1. No enrollment number is attached to either item. The confirmed health facts are the approval, the screening purpose, the inclusion of people above 45, the hospital, and the first receipt of that therapy.

Other illness counts this week, including cholera reports from Darfur, concerned infectious disease rather than these cancer tools. The cancer items stand apart from those outbreak tallies. They record a new screening approval and a first hospital use of ZI-MA4-1.